HomeNewsGlobal Pharma

Sterline Asia Announces its Participation in CPHI & PMEC INDIA 2024

Sterline Asia Announces its Participation in CPHI & PMEC INDIA 2024

Steriline Asia, a manufacturer of aseptic processing solutions for injectable drugs, has announced its participation at CPHI & PMEC India, held in Delhi from November 26-28, 2024.

Visitors will meet both the Indian team and the colleagues from Steriline headquarters at booth 10. D23, where they will learn about the company’s latest technological and process advancements, developed with a strong focus on sustainability and with the mission to make medicines more accessible and effective.

Steriline is dedicated to developing equipment that not only meets the needs of today’s pharmaceutical industry but also contributes to a more sustainable future for the pharmaceutical industry. Its strategy can be summed up in the concept of ‘Quality by Design’ (QbD), a systematic approach to pharmaceutical development and manufacturing that emphasises the importance of understanding and controlling processes from the outset. This ensures that the final product meets predefined criteria, building quality into the product rather than relying solely on end-product testing.

“The Quality by Design approach is essential for responding effectively and innovatively to the growing needs of the pharmaceutical market,” states Federico Fumagalli, Chief Sales Officer of Steriline.

“It allows us to understand and control every stage of the production process, ensuring that quality is built into the product from the outset and fully meets regulatory expectations. This approach enables us also to offer our customers not only continuous quality improvement but also greater efficiency, waste reduction and the ability to quickly adapt to the challenges the market faces, making both us and our customers more competitive and reliable,” Fumagalli added.

To develop new technologies, it is crucial to ensure there is collaboration at the engineering level between the company and regulatory bodies. Through periodic alignment meeting, Steriline’s technologies evolve in compliance with regulatory expectations and according to industry best practices. This close collaboration drives innovation, particularly in areas such as sterility and containment, ensuring that the new solutions are efficient and compliant with the latest requirements but, at the same time, they are also economically competitive.

Currently, to meet the needs of today’s pharmaceutical industry, the Steriline portfolio is split into two areas, one featuring advanced robotic technology and one with more traditional mechanical machines. The robotic solutions are ideal for high-value-added products requiring maximum flexibility and zero waste, while the mechanical machines are suited for large-scale and high-speed production.That said, the market is always in turmoil and its needs are constantly changing.

“The flexibility of production lines takes on a significant strategic value for drug manufacturers,” states Filippo Parini, Sales Area Manager of Steriline.

“Taking into consideration a trend observed in recent years - a notable increase in demand for self-injection devices - Steriline’s hybrid lines (composed by both robotic and mechanical elements) are designed to handle a variety of primary containers, such as cartridges for multi-dose injection pens, pre-filled syringes (PFS) for single-shot self-injection devices and vials for multi-dose applications, typically used in hospitals,” Parini stated.

“Steriline Asia will attend CPHI & PMEC, proud to be a company that combines the excellence and quality of Steriline's technologies with a deep understanding of the local Indian market,” declares Chiranjeevi Kondapaka, Chief Executive Officer of Steriline Asia.

“This combination allows us to develop innovative solutions that not only meet the highest international standards but are also perfectly aligned with the specific needs of our market. The mix of Italian technical expertise with great knowledge of the local context enables us to be more agile, competitive and ready to face the challenges of a rapidly evolving market,” Kondapaka added.

More news about: global pharma | Published by Aishwarya | October - 24 - 2024

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members